Background: This study looks to investigate how not meeting eligibility criteria affects postoperative outcomes following total joint arthroplasty surgery.
Methods: A retrospective review was conducted of total joint arthroplasty patients at a single academic institution. Demographics, laboratory values, and complications were recorded. Continuous and categorical variables were compared using the Student's T-test and the Chi-Square test, respectively. Multivariable analysis was used to control for confounding variables.
Results: Our study included 915 total hip and 1,579 total knee arthroplasty patients. For total hip and total knee arthroplasty, there were no significant differences in complications (P = .11 and .87), readmissions (P = .83 and .2), or revision surgeries (P = .3 and 1) when comparing those who met all criteria to those who did not. Total hip arthroplasty patients who did not meet two criteria had 16.1 higher odds (P = .02) of suffering a complication. There were no differences in complications (P = .34 and .41), readmissions (P = 1 and .55), or revision surgeries (P = 1 and .36) between ineligible patients treated by total joint arthroplasty surgeons and those who were not. Multivariable analysis demonstrated no eligibility factors were associated with outcomes for both total hip and knee arthroplasty.
Conclusions: There was no significant difference in outcomes between those who met all eligibility criteria and those who did not. Not meeting two criteria conferred significantly higher odds of suffering a complication for total hip arthroplasty patients. Total joint arthroplasty surgeons had similar outcomes to non-total joint surgeons, although their patient population was more complex.
Level Of Evidence: III.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arth.2024.02.056 | DOI Listing |
J Transl Med
January 2025
Medical College of YiChun University, Xuefu Road No 576, Yichun, 336000, Jiangxi, People's Republic of China.
Background: Artificial sweeteners (AS) have been widely utilized in the food, beverage, and pharmaceutical industries for decades. While numerous publications have suggested a potential link between AS and diseases, particularly cancer, controversy still surrounds this issue. This study aims to investigate the association between AS consumption and cancer risk.
View Article and Find Full Text PDFBMC Musculoskelet Disord
January 2025
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.
Background: The purposes of this study were to examine the reliability and factorial and convergent validity of a virtual performance measure (VPM) in patients with osteoarthritis (OA) of the hip joint and to compare the known-group validity of the VPM with traditional self-report and performance-based outcomes.
Methods: The VPM score was based on the results of 10 videos showing increasing difficulty in performing specific functional tasks. Patients were requested to choose the video that best reflected their own level of function.
BMJ Case Rep
January 2025
Orthopedic Surgery, Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, USA
Periprosthetic joint infection (PJI) is a devastating complication of total joint surgery. Surgical management of PJI has increased surgical risks and is costly to the healthcare system. This case study presents a unique clinical scenario involving a patient who was diagnosed with Lyme PJI at the total knee arthroplasty site after undergoing surgical management.
View Article and Find Full Text PDFSci Total Environ
January 2025
Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea. Electronic address:
Formaldehyde (HCHO), a major carbonyl compound in urban air, poses health risks due to its carcinogenic properties. However, the role of FT-PBL exchange in HCHO and the importance of vertical exchange on diurnal variations in HCHO remain unclear. This study investigated the diurnal variability of HCHO in Seoul's planetary boundary layer (PBL) during cold.
View Article and Find Full Text PDFPurpose: Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non-small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial.
Methods: Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC received three cycles of nivolumab once every 2 weeks plus one cycle of ipilimumab or three cycles of chemotherapy (on day 1 or days 1 and 8 of each 3-week cycle) followed by surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!